Heidelberg Pharma Attains Milestone Payment from Takeda

On January 29, 2026, Heidelberg Pharma AG, a biotech firm specializing in Antibody Drug Conjugates (ADCs), announced a milestone payment from Takeda. This result stems from Takeda's achievement in a clinical development milestone using Amanitin-based Antibody Drug Conjugate (ATAC) technology licensed from Heidelberg Pharma. The payment was triggered by dosing the first patient in a Phase I/II trial for solid tumors. Financial specifics are undisclosed.

CEO Dr. Dongzhou Jeffery Liu expressed satisfaction with Takeda's progress and acknowledgment of Heidelberg's ATAC technology. Three ATAC-based candidates are in clinical development, including Heidelberg's proprietary HDP-101 and HDP-102, underscoring the potential of their Amanitin-based technology.

Under their agreement, Takeda holds worldwide rights to develop and commercialize products using ATAC technology, with shared advancements benefiting both parties.